False-negative assessment of NanoNewron's NewroBus blood–brain barrier delivery platform in the JAX apical–domain–humanized TfR1 mouse
Year: 2026
Type: preprint
Abstract: Humanized transferrin receptor 1 (TfR1) mice are frequently used to evaluate blood–brain barrier (BBB) delivery, yet available strains differ in the extent and design of receptor humanization. We compared two NanoNewron NewroBus–based anti-TNFα constructs, NN-841 (D3 TfR1-binding module) and NN-843 (A2 module), in JAX #038212 (humanized apical domain), Cyagen C001584 (human extracellular-domain CDS model), Cyagen C001860 (human extracellular-domain genomic replacement model), and wild-type controls. Thirty mice received intravenous injections and were evaluated 24 h later. Brain parenchymal-fraction signals were reported in all 12 Cyagen mice, but in none of six JAX or 12 wild–type animals. Serum concentrations were measurable in every group and followed the same rank order for both constructs: Cyagen-CDS>Cyagen–HU>wild type >JAX. Mean CDS–to–JAX serum ratios were approximately 13-–fold for both constructs. Compared with the Cyagen–HU strain, the CDS strain showed higher parenchymal concentrations; the ratio of mean parenchymal to mean serum concentration increased prominently for NN–841, but only modestly for NN–843. These findings indicate that model choice influences 24–h circulating concentrations and apparent BBB delivery. Circulating soluble human TfR1–mediated stabilization and endothelial TfR1–dependent transport are plausible, untested explanations for strain-dependent differences. A negative brain-delivery result in JAX #038212 alone cannot be taken as evidence that NewroBus lacks BBB delivery activity
Authors: Ishita Chakraborty, Tao Yin, Luciano D'Adamio
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236472863
